Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Biomed Vi-conjugate...

    Biomed Vi-conjugate typhoid vaccine- 2 batches Not of Standard Quality, informs CDSCO

    Written by Ruby Khatun Khatun Published On 2018-03-16T14:01:51+05:30  |  Updated On 16 March 2018 2:01 PM IST
    Biomed Vi-conjugate typhoid vaccine- 2 batches Not of Standard Quality, informs CDSCO

    New Delhi: Through a recent notification, the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, Directorate General of Health Services has informed that it has found two batches of Peda Typh, a Vi-conjugate vaccine for typhoid manufactured by Biomed, a Ghaziabad based firm as substandard in quality tests.


    The notice states that it has been reported that the samples of Peda Typh (Vi Conjugate Typhoid Vaccine) (One dose), Batch No. TC010915 (CDL No. 453/2018) and Batch No. TC010417 (CDL No. 454/2018), manufactured by M/s Biomed Pvt. Ltd. Ghaziabad have been declared as Not of Standard Quality (NSQ) by CDL, Kasauli with respect to Vi Polysaccharide content vide test report no. CDL/2018/752,753 and CDL/2018/754,755 dated 09.02.2018.


    The Drug Controller General of India (DCGI) on March 14 requested all States/UT Drugs Controllers, CDSCO Zonal/Sub-Zonal officers to direct the inspectorate staffs under their control to keep a strict vigil on the movement of said product (Batch Nos.TC010915 & TC010417) in the market.


    Peda Typh, manufactured by Biomed, is the first commercially available Vi-antigen conjugated typhoid vaccine in India. It is used for active immunization against Salmonella Typhi in infants, children, and adults.


    The Typhoid Vi Conjugate vaccine have been demonstrated to include ‘T’ Cell-dependent response with a much higher antibody. The conjugate Vi antigen vaccine also elicits booster response as is common to all conjugated vaccines.


    A clear to slightly turbid solution containing purified Vi capsular polysaccharide of Salmonella typhi (Strain Ty2) conjugated with Tetanus toxoid protein for prevention of typhoid fever


    Typhoid fever, also known simply as typhoid, is a bacterial infection due to Salmonella Typhi that causes symptoms.Symptoms may vary from mild to severe and usually begin six to thirty days after exposure. Often there is a gradual onset of a high fever over several days.


    It is a communicable disease that affects 21 million people and causes 222,000 deaths annually worldwide. Typhoid is spread by eating or drinking food or water contaminated with the feces of an infected person. Risk factors include poor sanitation and poor hygiene.


    Below is the attached notification.
    BiomedBiomed Pvt LtdCDSCOCentral Drugs Standard Control OrganisationDirectorate General of Health ServicesdrugsimmunizationMinistry of Health and Family WelfarePeda TyphSalmonella Typhisubstandardsubstandard qualitytyphoidTyphoid vaccinevaccineVi-conjugate

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok